Tarik Demir

The Ohio State University Comprehensive Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (1)

Devalingam Mahalingam

Associate Professor of Medicine

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tarik Demir

Research Interests

Explore related searches

Contact this professor

Articles (10)

Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden

Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension

A phase II trial to evaluate clinical efficacy, pharmacodynamics and exploratory analysis of pemetrexed in relation to MLL4 and UTX alteration status in patients with relapsed/refractory metastatic urothelial carcinoma and other solid tumors.

Clinical and molecular outcomes of gastrointestinal malignancies treated with early phase studies: A retrospective single-center experience.

Double lung transplantation in patients with recent history of malignancy.

Abstract CT163: Double lung transplantation in patients with metastatic lung-limited non-small cell lung carcinoma (NSCLC): A case series

Abstract CT211: Double lung transplantation in patients with recent history of malignancy

Abstract CT234: [DREAM] Double lung transplant registry aimed for lung-limited malignancies - A prospective registry study for medically refractory cancers

Abstract 5808: Differential clinical outcomes of immune vs non-immune based therapeutics in gastrointestinal malignancies: A retrospective, single center experience of early phase studies

Abstract 719: Clinical and molecular differences suggest different responses to immune checkpoint inhibitors in microsatellite-stable solid tumors with high tumor mutational burden

Collaborators (1)

Devalingam Mahalingam

Make your next move.